Head-to-head evidence
Icotinib vs Lazertinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
Icotinib
Developed by Betta Pharmaceuticals Co.
NCT01040780 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled trial with 200 participants assigned to icotinib and 199 to gefitinib, and its primary endpoint was the clinical measure of progression-free survival. Although the reported median favored icotinib, the statistical significance of the primary comparison is not stated, so the result is unclear rather than definitively positive.
Next expected readout: December 2030 · NCT06955325 (registry estimate)
Lazertinib
Marketed by Johnson & Johnson and partners
NCT04248829 · Phase 3 · completed
The trial randomized 393 participants to lazertinib or an active gefitinib control and used quadruple masking, with investigators and outcome assessors blinded. Its primary clinical endpoint, progression-free survival, favored lazertinib numerically, but statistical significance is not reported, so the result cannot be classified as definitively met.
Next expected readout: December 2026 · NCT05463224 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Icotinib's landscape · Lazertinib's landscape